Can a new pill tame childhood cancers that Won't quit?

NCT ID NCT07773454

NEW Not yet recruiting Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

First seen Aug 19, 2026 · Last updated Aug 19, 2026

Summary

This early-stage trial is testing an experimental drug called zanzalintinib in children and teens with solid tumors that have returned or not responded to standard treatment. The main goals are to find the highest safe dose and to see how well the drug is tolerated. Participants receive the drug and are closely monitored for side effects and how the drug moves through their bodies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
zanzalintinib (also known as XL092), an oral drug being tested for its safety and tolerability in children with certain cancers
What this could lead to
If successful, this could establish a safe dose of zanzalintinib for children and potentially offer a new treatment option for hard-to-treat pediatric solid tumors.
What could go wrong
This is an early-phase trial with a small number of participants, so the drug may not prove effective or may cause significant side effects. The results will only guide further study, not confirm a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.